Display options
Cite
Le J, Schiller DS. Aerosolized Delivery of Antifungal Agents. Curr Fungal Infect Rep. 2010;4(2):96-102doi: 10.1007/s12281-010-0011-0.
Le, J., & Schiller, D. S. (2010). Aerosolized Delivery of Antifungal Agents. Current fungal infection reports, 4(2), 96-102. https://doi.org/10.1007/s12281-010-0011-0
Le, Jennifer, and Schiller, Daryl S. "Aerosolized Delivery of Antifungal Agents." Current fungal infection reports vol. 4,2 (2010): 96-102. doi: https://doi.org/10.1007/s12281-010-0011-0
Le J, Schiller DS. Aerosolized Delivery of Antifungal Agents. Curr Fungal Infect Rep. 2010 Jun;4(2):96-102. doi: 10.1007/s12281-010-0011-0. Epub 2010 Apr 13. PMID: 20502511; PMCID: PMC2868999.
Copy Download .nbib Format: NLM
Share it on

Curr Fungal Infect Rep. 2010 Jun;4(2):96-102. doi: 10.1007/s12281-010-0011-0. Epub 2010 Apr 13.

Aerosolized Delivery of Antifungal Agents.

Current fungal infection reports

Jennifer Le, Daryl S Schiller

PMID: 20502511 PMCID: PMC2868999 DOI: 10.1007/s12281-010-0011-0

Abstract

Pulmonary infections caused by Aspergillus species are associated with significant morbidity and mortality in immunocompromised patients. Although the treatment of pulmonary fungal infections requires the use of systemic agents, aerosolized delivery is an attractive option in prevention because the drug can concentrate locally at the site of infection with minimal systemic exposure. Current clinical evidence for the use of aerosolized delivery in preventing fungal infections is limited to amphotericin B products, although itraconazole, voriconazole, and caspofungin are under investigation. Based on conflicting results from clinical trials that evaluated various amphotericin B formulations, the routine use of aerosolized delivery cannot be recommended. Further research with well-designed clinical trials is necessary to elucidate the therapeutic role and risks associated with aerosolized delivery of antifungal agents. This article provides an overview of aerosolized delivery systems, the intrapulmonary pharmacokinetic properties of aerosolized antifungal agents, and key findings from clinical studies.

References

  1. Pulm Pharmacol Ther. 2008 Dec;21(6):855-9 - PubMed
  2. Transpl Infect Dis. 2006 Mar;8(1):13-20 - PubMed
  3. Chest. 2005 Jan;127(1):335-71 - PubMed
  4. Clin Infect Dis. 2008 May 1;46(9):1401-8 - PubMed
  5. Chest. 2005 Nov;128(5):3711-6 - PubMed
  6. Pediatr Pulmonol. 2007 Apr;42(4):307-13 - PubMed
  7. Eur J Clin Microbiol Infect Dis. 1997 May;16(5):364-8 - PubMed
  8. Transplant Proc. 2008 Nov;40(9):3090-3 - PubMed
  9. Ann Pharmacother. 2006 Dec;40(12):2148-54 - PubMed
  10. Ann Hematol. 1995 Dec;71(6):287-91 - PubMed
  11. Am J Transplant. 2006 Dec;6(12):3008-16 - PubMed
  12. Antimicrob Agents Chemother. 1995 Aug;39(8):1784-9 - PubMed
  13. Transplantation. 2001 Aug 15;72(3):545-8 - PubMed
  14. Pharm Res. 2006 May;23(5):901-11 - PubMed
  15. Expert Opin Drug Saf. 2007 Sep;6(5):523-32 - PubMed
  16. Antimicrob Agents Chemother. 1990 Jan;34(1):29-32 - PubMed
  17. J Pharm Sci. 1997 Sep;86(9):1066-9 - PubMed
  18. Clin Infect Dis. 1999 Dec;29(6):1402-7 - PubMed
  19. Transpl Infect Dis. 2007 Jun;9(2):121-5 - PubMed
  20. Leuk Lymphoma. 1992 Oct;8(3):229-33 - PubMed
  21. Antimicrob Agents Chemother. 2006 May;50(5):1852-4 - PubMed
  22. Eur Respir J. 2002 Jul;20(1):122-6 - PubMed
  23. Int J Pharm. 2005 May 30;296(1-2):12-25 - PubMed
  24. Infect Dis Clin North Am. 2006 Sep;20(3):679-97 - PubMed
  25. Antimicrob Agents Chemother. 2006 May;50(5):1878-80 - PubMed
  26. Antimicrob Agents Chemother. 2006 Apr;50(4):1552-4 - PubMed
  27. Infection. 1994 Mar-Apr;22(2):143-8 - PubMed
  28. Pharmacotherapy. 2000 Feb;20(2):166-81 - PubMed
  29. Antimicrob Agents Chemother. 2007 Apr;51(4):1253-8 - PubMed
  30. J Pharm Pharmacol. 2005 Oct;57(10):1289-95 - PubMed
  31. Eur Respir J. 1995 Aug;8(8):1263-8 - PubMed
  32. Eur J Pharm Biopharm. 2006 Jun;63(2):95-102 - PubMed
  33. J Infect. 2007 Jul;55(1):68-74 - PubMed
  34. Clin Infect Dis. 2008 Feb 1;46(3):327-60 - PubMed
  35. J Antimicrob Chemother. 2006 Jun;57(6):1153-60 - PubMed
  36. Antimicrob Agents Chemother. 1998 Jul;42(7):1597-600 - PubMed
  37. Blood. 1999 Jun 1;93(11):3654-61 - PubMed
  38. Eur J Pharm Biopharm. 2009 May;72(1):199-205 - PubMed
  39. Transplantation. 2004 Jan 27;77(2):232-7 - PubMed
  40. Am J Clin Oncol. 1993 Feb;16(1):43-6 - PubMed
  41. Chest. 1996 Aug;110(2):498-505 - PubMed
  42. Antimicrob Agents Chemother. 2006 Jun;50(6):2122-31 - PubMed
  43. Ann Genet. 1996;39(1):10-5 - PubMed
  44. Pharmacotherapy. 2002 Mar;22(3 Pt 2):71S-79S - PubMed
  45. Chest. 1999 Sep;116(3):775-88 - PubMed
  46. Bone Marrow Transplant. 2004 Sep;34(5):467-8 - PubMed
  47. J Heart Lung Transplant. 2001 Dec;20(12):1274-81 - PubMed
  48. Am J Transplant. 2006 Nov;6(11):2765-73 - PubMed
  49. J Neurosci Nurs. 2004 Aug;36(4):231-5 - PubMed
  50. Respir Care. 2007 Jul;52(7):866-84 - PubMed
  51. Pharmacotherapy. 2002 Mar;22(3 Pt 2):80S-85S - PubMed
  52. Transplantation. 2003 May 15;75(9):1571-4 - PubMed
  53. Eur Respir J. 2001 Jul;18(1):228-42 - PubMed
  54. J Heart Lung Transplant. 2009 Feb;28(2):170-5 - PubMed

Publication Types